Herpikind 400 Tablet DT contains Acyclovir 400 mg, an antiviral agent indicated for the treatment of herpes simplex virus infections, including orolabial herpes, genital herpes, and herpes zoster (shingles). Acyclovir acts by inhibiting viral DNA polymerase, thereby interfering with viral replication and reducing the severity and duration of symptoms. Herpikind 400 Tablet DT is formulated as a dispersible tablet, facilitating ease of administration and rapid onset of action, particularly beneficial for patients with difficulty swallowing conventional tablets. This medication is typically prescribed to initiate therapy at the earliest signs of infection to maximize therapeutic outcomes. Dosage and duration depend on the type and severity of the infection, patient age, and renal function, and should be determined by a healthcare professional. Common adverse effects may include headache, nausea, diarrhea, and occasional renal toxicity, especially in patients with pre-existing kidney impairment. Adequate hydration during treatment is recommended to minimize renal adverse effects. Herpikind 400 Tablet DT is contraindicated in patients with known hypersensitivity to Acyclovir or any component of the formulation. Caution is advised in immunocompromised patients and those with renal dysfunction. This medication should be used under medical supervision to ensure safe and effective treatment of herpes virus infections.